Human engineered cardiac tissues created from BRAF mutant induced pluripotent stem cells exhibited a hypertrophic phenotype with significantly increased tissue size and twitch force compared to wild-type controls.
A novel 3D human engineered cardiac tissue model using BRAF mutant iPSCs successfully recapitulates key aspects of hypertrophic cardiomyopathy, offering a new platform for mechanistic study and drug screening.
Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death that often goes undetected in the general population. HCM is also prevalent in patients with cardio-facio-cutaneous syndrome (CFCS), which is a genetic disorder characterized by aberrant signaling in the RAS/MAPK signaling cascade. Understanding the mechanisms of HCM development in such RASopathies may lead to novel therapeutic strategies, but relevant experimental models of the human condition are lacking. Therefore, the objective of this study was to develop the first 3D human engineered cardiac tissue (hECT) model of HCM. The hECTs were created using human cardiomyocytes obtained by directed differentiation of induced pluripotent stem cells derived from a patient with CFCS due to an activating BRAF mutation. The mutant myocytes were directly conjugated at a 3:1 ratio with a stromal cell population to create a tissue of defined composition. Compared to healthy patient control hECTs, BRAF-hECTs displayed a hypertrophic phenotype by culture day 6, with significantly increased tissue size, twitch force, and atrial natriuretic peptide (ANP) gene expression. Twitch characteristics reflected increased contraction and relaxation rates and shorter twitch duration in BRAF-hECTs, which also had a significantly higher maximum capture rate and lower excitation threshold during electrical pacing, consistent with a more arrhythmogenic substrate. By culture day 11, twitch force was no longer different between BRAF and wild-type hECTs, revealing a temporal aspect of disease modeling with tissue engineering. Principal component analysis identified diastolic force as a key factor that changed from day 6 to day 11, supported by a higher passive stiffness in day 11 BRAF-hECTs. In summary, human engineered cardiac tissues created from BRAF mutant cells recapitulated, for the first time, key aspects of the HCM phenotype, offering a new in vitro model for studying intrinsic mechanisms and screening new therapeutic approaches for this lethal form of heart disease.
Cashman et al. (Tue,) conducted a other in Hypertrophic Cardiomyopathy (HCM) in Cardio-facio-cutaneous syndrome (CFCS). BRAF-mutant iPSC-derived human engineered cardiac tissues (hECTs) vs. Wild-type iPSC-derived hECTs was evaluated on Hypertrophic phenotype characteristics (tissue size, twitch force, and twitch dynamics). Human engineered cardiac tissues created from BRAF mutant induced pluripotent stem cells exhibited a hypertrophic phenotype with significantly increased tissue size and twitch force compared to wild-type controls.